Common Mistakes When Using Anabolic Steroids and How to Avoid Them

Pre-Cycle Mistakes

Mistake 1 — No Pre-Cycle Bloodwork

Running a first cycle without baseline bloodwork is the single most common and most consequential mistake in AAS use. Without a baseline, you cannot interpret mid-cycle results, cannot confirm PCT success, and cannot identify whether something has gone wrong during the cycle.

The correct approach: complete a full pre-cycle panel 1–2 weeks before the first injection:

• Total testosterone, free testosterone, LH, FSH, SHBG, E2
• Complete blood count — haematocrit, haemoglobin, platelets
• Lipids — HDL, LDL, triglycerides
• Liver enzymes — ALT, AST, ALP, GGT
• Blood pressure — home readings over 3 days
• PSA if over 40

Mistake 2 — No PCT Ready Before Starting

The most violated pre-cycle rule: sourcing PCT after the cycle ends. By the time a cycle finishes, ordering and waiting for Nolvadex or Clomid means days or weeks of hormonal crash with no intervention. PCT must be in hand before day 1 of the cycle.

Mistake 3 — Starting Too Young

Using AAS before the HPG axis has fully matured — typically before the mid-to-late 20s — risks impairing natural peak testosterone development. Younger users who suppress a still-developing HPG axis can create long-term hormonal damage that is significantly harder to reverse than suppression in mature adults.

Mistake 4 — Insufficient Training Foundation

AAS amplify the response to good training — they do not replace it. Starting a cycle without at minimum 1–2 years of consistent progressive overload training produces disappointing results and wastes the health cost of the cycle. The anabolic environment created by AAS requires an adequate training stimulus to translate into muscle.

Compound Selection Mistakes

Mistake 5 — Starting with a Stack Instead of One Compound

Running multiple compounds on a first cycle makes it impossible to identify what is causing any side effect that appears. If you run testosterone, Deca and Dianabol simultaneously and develop gynecomastia — is it from testosterone aromatisation, nandrolone's progestin activity, or Dianabol's estrogenic effect? You cannot know. The correct first cycle is testosterone only.

Mistake 6 — Using Trenbolone Too Early

Trenbolone is the most demanding injectable in common use — cardiovascular strain, androgenic effects, psychological effects including insomnia and anxiety, and prolactin management. Running Trenbolone before you have experience with milder compounds and a clear baseline profile is a serious error. Trenbolone should be reserved for users who have completed multiple testosterone-only or testosterone + one-compound cycles and understand their own response to AAS.

Mistake 7 — Oral-Only Cycles as the Base

Oral-only cycles suppress testosterone without providing stable androgen replacement. The result is low-testosterone symptoms during the cycle itself — reduced libido, fatigue, mood disruption — while also imposing hepatotoxicity. Injectable testosterone as the base is superior in every practical way for cycle planning.

Mistake 8 — Stacking SARMs with AAS for More Gains

Adding highly suppressive SARMs like LGD-4033 or RAD-140 to a testosterone cycle adds meaningful suppression and lipid impact without adding meaningful anabolic effect beyond what testosterone already provides. If more anabolism is the goal, increasing testosterone dose or adding a proven injectable is a better risk/benefit calculation than stacking SARMs.

Dosing Mistakes

Mistake 9 — Too High a Dose on the First Cycle

The most common beginner dosing error. More testosterone does not produce proportionally more muscle — it produces proportionally more side effects. 500 mg/week on a first cycle provides no meaningful advantage in lean mass over 300–400 mg/week but significantly more estrogen conversion, more androgenic effects and more cardiovascular impact. Start conservatively — you can always run a higher dose on a subsequent cycle once you know your baseline response.

Mistake 10 — Extending the Cycle Because Gains Are Good

"Gains are good so I'll run it to 16 weeks instead of 12" — the cumulative risk framework from 2026 research shows that the majority of lean mass gain from a testosterone cycle is achieved in the first 10–12 weeks. Extending beyond this produces diminishing anabolic returns while accelerating cardiovascular, hepatic and suppression costs. Longer cycles are not simply more of the same — they represent disproportionately increased risk.

Mistake 11 — Running Oral Steroids Too Long

17-alpha alkylated oral steroids — Dianabol, Winstrol, Superdrol (Methyldrostanolone) — are limited to 4–6 weeks maximum (3–4 weeks for Superdrol). Running them longer compounds hepatotoxicity without proportional anabolic benefit. Never run two hepatotoxic orals simultaneously.

Estrogen Management Mistakes

Mistake 12 — Using AI Prophylactically

The most common estrogen management error: starting Arimidex or Aromasin at the beginning of the cycle "just in case." Aromatase inhibitors should be used reactively — only when symptoms of high estrogen appear (nipple sensitivity, puffy nipples, significant water retention, mood instability). Prophylactic AI use frequently crashes E2 to hypogonadal levels.

Mistake 13 — Crashed Estrogen

Crashing E2 with excessive AI dosing produces a distinct and unpleasant symptom profile: joint pain, low libido, depression, cognitive impairment, dry skin and poor sleep. Paradoxically, these symptoms mirror low testosterone — making it difficult to distinguish from inadequate androgen effect. Crashed E2 is a frequent cause of "my cycle isn't working" complaints that are actually caused by over-suppression of estrogen.

Mistake 14 — Using AI as PCT

Aromatase inhibitors reduce estrogen but do not stimulate LH or FSH production. Using Arimidex or Aromasin as post-cycle therapy instead of SERMs does not restore natural testosterone — it suppresses estrogen while testosterone remains low. AI-only "PCT" is one of the most common and most damaging errors in post-cycle management. PCT requires Nolvadex or Clomid — not an AI.

Mistake 15 — Ignoring Prolactin on 19-Nor Cycles

Nandrolone (Deca) and Trenbolone are 19-nor compounds that can elevate prolactin through progestin activity. Running standard PCT with SERMs after a 19-nor cycle without checking prolactin can result in persistent sexual dysfunction — particularly low libido and erectile issues that do not resolve with Nolvadex. Address prolactin with Cabergoline before or alongside SERMs.

Injection Technique Mistakes

Mistake 16 — Non-Sterile Technique

Injection site infections are almost entirely caused by poor sterile technique — not by the compound itself. Every injection must use a new sterile needle, alcohol swab at the injection site, and hands washed before preparation. Reusing needles, injecting through the same site repeatedly without rotation, or using compromised vials are direct routes to abscess formation that can require surgical drainage.

Mistake 17 — Not Rotating Injection Sites

Repeatedly injecting the same site builds scar tissue — progressively harder tissue that reduces compound absorption and increases injection pain. Rotating across multiple sites — glutes (bilateral), quads (bilateral), delts (bilateral) — distributes the tissue load and maintains absorption efficiency throughout a long cycle.

Mistake 18 — Wrong Needle Size

• Intramuscular (glutes/quads): 23–25 gauge, 1–1.5 inch — reaches muscle without excessive tissue trauma
• Intramuscular (delts): 25 gauge, 1 inch — smaller muscle requires shorter needle
• Subcutaneous (peptides): 29–31 gauge, 0.5 inch insulin syringe
• Drawing: 18–21 gauge for drawing from vial — switch to injection needle before injecting

On-Cycle Monitoring Mistakes

Mistake 19 — No Mid-Cycle Bloodwork

Haematocrit can reach dangerous levels (above 52%) without symptoms. LDL can spike dramatically within 4–6 weeks of oral steroid use without any clinical signs. Blood pressure can climb to levels that require intervention without the user noticing. Mid-cycle bloodwork at week 4–6 is not optional — it is the only way to identify problems before they become serious.

Mistake 20 — Ignoring Blood Pressure

Elevated blood pressure on cycle is common and manageable — uncontrolled sustained hypertension during a cycle is a cardiovascular risk that compounds across the duration of use. Measure blood pressure at home, same time each day. If consistently above 140/90 — reduce dose, address water retention, or consider a blood pressure medication consultation.

Mistake 21 — Skipping Cardiac Monitoring for Long-Term Users

Users with 3+ years of AAS history or multiple cycles should incorporate annual echocardiography. Left ventricular hypertrophy develops silently — no symptoms until advanced. This is now a standard recommendation in 2026 harm reduction guidance. See our 2026 Evidence Guide for the complete cardiovascular monitoring framework.

PCT Mistakes

Mistake 22 — Starting PCT Too Early

The most common PCT timing error. Starting PCT while long-ester steroids are still active — before they have cleared to sub-therapeutic levels — wastes the SERM and may worsen suppression. For testosterone enanthate or cypionate: wait 14 days after the last injection. For Deca: wait 21 days. For short esters (propionate, acetate): 3–4 days. See the full ester timing table in our PCT guide.

Mistake 23 — Underdosing PCT

10 mg of Nolvadex "just in case" is not PCT. Therapeutic doses are required to drive meaningful LH and FSH recovery. Standard Nolvadex PCT: 40 mg/day weeks 1–2, 20 mg/day weeks 3–4. Underdosing produces incomplete HPG axis recovery that bloodwork will reveal — testosterone below 400 ng/dL four weeks after PCT completion indicates inadequate protocol.

Mistake 24 — Stopping PCT Early

Feeling better at week 2 of PCT does not mean recovery is complete. The HPG axis takes the full 4–6 weeks of SERM therapy to fully reinstate LH and FSH signalling. Stopping early because subjective symptoms have improved leaves the hormonal recovery incomplete — verified only by bloodwork at 4 weeks post-PCT.

Mistake 25 — No PCT After SARMs

"SARMs don't need PCT" is among the most damaging myths in performance enhancement. LGD-4033, RAD-140, S23 and YK-11 all produce meaningful HPG suppression requiring full SERM PCT. Stopping without PCT leads to weeks or months of hypogonadal symptoms. See our SARMs vs Steroids guide for compound-specific PCT requirements.

Sourcing Mistakes

Mistake 26 — Choosing Cheapest Over Verified

The 2024 AAS testing programme found over 52% of user-submitted samples from unverified sources had quality problems — wrong compound or wrong concentration. The cheapest option is statistically more likely to be underdosed, mislabelled or contaminated than a verified pharmaceutical-grade product. Source selection is harm reduction — not a premium. See our guide: How to Spot Fake Steroids, Peptides and SARMs.

Mistake 27 — No Verification Check

Established manufacturers including Dragon Pharma include verification codes that can be checked on the manufacturer's website. Purchasing a product and not verifying it — when the verification mechanism exists — leaves a quality question that takes 30 seconds to resolve. Verify every vial before first use.

Women-Specific Mistakes

Mistake 28 — Too High a Dose or Too Androgenic a Compound

Women are significantly more sensitive to androgenic effects than men. Virilisation — voice deepening, clitoral enlargement, body and facial hair — can develop rapidly at doses men would consider mild, and some changes are irreversible. Women should use the lowest effective dose of the lowest-androgenicity compound available: Anavar at 5–20 mg/day or Primobolan at 25–75 mg/week injectable.

Mistake 29 — Ignoring Early Virilisation Signs

Voice changes are the earliest irreversible virilisation marker — stop immediately at the first sign of voice deepening. Clitoral changes can begin earlier and may be reversible if the compound is stopped promptly. Many women continue past early warning signs hoping the effect will stop — it will not while the compound is active.

Mistake 30 — Not Considering Peptides First

For most women's performance, recovery and body composition goals, peptides — GH secretagogues, BPC-157, TB-500, Tesamorelin — produce meaningful results without androgenic risk. Women who use AAS without first considering peptide options may be accepting hormonal risk unnecessarily. See our Peptides vs Steroids guide.

Frequently Asked Questions